Arvinas Inc - Understand $arvn stock

$ARVN Market Cap: $1.712 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$161.1M

TTM

Gross Margin

Net Earnings

-$308.6M

TTM

Current Assets

$1.150B

Q3 2024

Current Liabilities

$275.9M

Q3 2024

Current Ratio

416.64%

Q3 2024

Total Assets

$1.167B

Q3 2024

Total Liabilities

$581.1M

Q3 2024

Book Value

$586.0M

Q3 2024

Cash

$85.20M

Q3 2024

P/E

-5.549

Nov 14, 2024 EST

Free Cash Flow

-$259.9M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$78.50M	$131.4M	$46.70M	$21.80M	$43.00M	$14.30M	$7.579M	$6.670M
YoY Change	-40.26%	181.37%	114.22%	-49.3%	200.7%	88.68%	13.63%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$78.50M	$131.4M	$46.70M	$21.80M	$43.00M	$14.30M	$7.579M	$6.670M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$100.3M	$79.60M	$61.60M	$38.30M	$27.31M	$12.93M	$3.550M	$3.200M
YoY Change	26.01%	29.22%	60.84%	40.24%	111.21%	264.23%	10.94%
% of Gross Profit
Research & Development	$379.7M	$315.0M	$180.4M	$108.4M	$67.20M	$45.19M	$28.79M	$19.94M
YoY Change	20.54%	74.61%	66.42%	61.31%	48.71%	56.96%	44.38%
% of Gross Profit
Depreciation & Amortization	$4.800M	$6.300M	$4.800M	$3.200M	$1.600M	$706.0K	$347.4K	$440.0K
YoY Change	-23.81%	31.25%	50.0%	100.0%	126.63%	103.23%	-21.05%
% of Gross Profit
Operating Expenses	$480.0M	$394.6M	$242.0M	$146.7M	$94.50M	$58.13M	$32.34M	$23.14M
YoY Change	21.64%	63.06%	64.96%	55.24%	62.58%	79.74%	39.75%
Operating Profit	-$401.5M	-$263.2M	-$195.3M	-$124.9M	-$51.50M	-$43.80M	-$24.76M
YoY Change	52.55%	34.77%	56.37%	142.52%	17.57%	76.9%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$0.00	$12.00M	$100.0K	$100.0K	$100.0K	$57.44K	$150.0K	$350.0K
YoY Change	-100.0%	11900.0%	0.0%	0.0%	74.09%	-61.71%	-57.14%
% of Operating Profit
Other Income/Expense, Net	$37.60M	$12.20M	$4.300M	$5.600M	$5.900M	$2.322M	$554.2K	$1.680M
YoY Change	208.2%	183.72%	-23.21%	-5.08%	154.13%	318.94%	-67.01%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	-$363.9M	-$251.0M	-$191.0M	-$119.3M	-$70.29M	-$41.48M	-$24.05M	-$14.44M
YoY Change	44.98%	31.41%	60.06%	69.77%	69.46%	72.47%	66.55%
Income Tax	$900.0K	$20.90M	$0.00	$0.00	$0.00	$0.00	$0.00	-$90.00K
% Of Pretax Income
Net Earnings	-$367.3M	-$282.5M	-$191.0M	-$119.3M	-$70.30M	-$41.48M	-$24.05M	-$14.35M
YoY Change	30.02%	47.91%	60.1%	69.7%	69.48%	72.48%	67.59%
Net Earnings / Revenue	-467.9%	-214.99%	-408.99%	-547.25%	-163.49%	-290.07%	-317.32%	-215.14%
Basic Earnings Per Share	-$6.62	-$5.31	-$3.82	-$3.02	-$2.13
Diluted Earnings Per Share	-$6.62	-$5.31	-$3.82	-$3.02	-$2.13	-$1.328M	-$771.3K	-$460.2K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$1.261B	$1.205B	$1.503B	$688.5M	$280.9M	$187.8M	$39.20M	$35.60M
YoY Change	4.62%	-19.79%	118.24%	145.11%	49.57%	379.08%	10.11%
Cash & Equivalents	$311.7M	$81.30M	$108.3M	$588.4M	$9.200M	$3.200M	$30.90M	$5.100M
Short-Term Investments	$949.3M	$1.124B	$1.394B	$100.2M	$271.7M	$184.6M	$8.300M	$30.50M
Other Short-Term Assets	$12.00M	$26.90M	$24.20M	$6.100M	$3.700M	$2.800M	$300.0K	$300.0K
YoY Change	-55.39%	11.16%	296.72%	64.86%	32.14%	833.33%	0.0%
Inventory
Prepaid Expenses
Receivables	$0.00	$1.000M	$15.00M	$1.000M	$0.00	$2.800M	$25.00M	$0.00
Other Receivables	$7.200M	$7.000M	$10.70M	$7.400M	$6.300M	$2.200M	$1.000M	$1.400M
Total Short-Term Assets	$1.280B	$1.240B	$1.553B	$703.1M	$290.9M	$195.7M	$65.50M	$37.30M
YoY Change	3.23%	-20.12%	120.81%	141.7%	48.65%	198.78%	75.6%
Property, Plant & Equipment	$14.00M	$17.80M	$16.60M	$14.30M	$10.70M	$3.600M	$1.300M	$600.0K
YoY Change	-21.35%	7.23%	16.08%	33.64%	197.22%	176.92%	116.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.40M	$10.80M	$12.50M	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-3.7%	-13.6%
Total Long-Term Assets	$24.40M	$28.60M	$29.10M	$14.30M	$10.70M	$3.600M	$1.300M	$600.0K
YoY Change	-14.69%	-1.72%	103.5%	33.64%	197.22%	176.92%	116.67%
Total Assets	$1.305B	$1.269B	$1.582B	$717.4M	$301.6M	$199.3M	$66.80M	$37.90M
YoY Change
Accounts Payable	$92.20M	$5.700M	$31.30M	$7.100M	$4.600M	$2.800M	$600.0K	$1.600M
YoY Change	1517.54%	-81.79%	340.85%	54.35%	64.29%	366.67%	-62.5%
Accrued Expenses	$1.900M	$60.50M	$24.20M	$19.80M	$8.300M	$4.000M	$3.500M	$1.700M
YoY Change	-96.86%	150.0%	22.22%	138.55%	107.5%	14.29%	105.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due					$0.00	$200.0K	$200.0K	$100.0K
YoY Change					-100.0%	0.0%	100.0%
Total Short-Term Liabilities	$257.1M	$295.1M	$261.7M	$49.10M	$32.80M	$23.00M	$17.90M	$10.00M
YoY Change	-12.88%	12.76%	432.99%	49.7%	42.61%	28.49%	79.0%
Long-Term Debt	$800.0K	$1.000M	$1.000M	$2.000M	$2.000M	$2.000M	$200.0K	$300.0K
YoY Change	-20.0%	0.0%	-50.0%	0.0%	0.0%	900.0%	-33.33%
Other Long-Term Liabilities	$386.7M	$407.8M	$537.2M	$24.00M	$40.10M	$37.60M	$48.60M	$3.600M
YoY Change	-5.17%	-24.09%	2138.33%	-40.15%	6.65%	-22.63%	1250.0%
Total Long-Term Liabilities	$387.5M	$408.8M	$538.2M	$26.00M	$42.10M	$39.60M	$48.80M	$3.900M
YoY Change	-5.21%	-24.04%	1970.0%	-38.24%	6.31%	-18.85%	1151.28%
Total Liabilities	$644.6M	$703.9M	$799.9M	$75.10M	$75.00M	$62.60M	$66.60M	$13.90M
YoY Change	-8.42%	-12.0%	965.11%	0.13%	19.81%	-6.01%	379.14%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	55.50M shares	53.20M shares	50.00M shares	39.50M shares	32.90M shares
Diluted Shares Outstanding	55.50M shares	53.20M shares	50.00M shares	39.50M shares	32.90M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $1.7123 Billion

About Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 445 full-time employees. The company went IPO on 2018-09-27. The firm uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Industry: Pharmaceutical Preparations Peers: Axsome Therapeutics Inc Pacira Biosciences Inc Cassava Sciences Inc Corcept Therapeutics Inc Harmony Biosciences Holdings Inc Johnson & Johnson Prestige Consumer Healthcare Inc